Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Skin Neoplasms × relatlimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

Sirolimus 3 aldesleukin 2 Tacrolimus 2 Cyclosporine 2 relatlimab 1 abobotulinumtoxinA 1 Vemurafenib 1 Sodium Chloride 1 Prednisone 1 Nivolumab 1 Mycophenolic Acid 1 Meloxicam 1 Ipilimumab 1 Interleukins 1 Interleukin-2 1 Everolimus 1 Bleomycin 1 Azathioprine 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Bristol-Myers Squibb

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡